Mendus

Mendus has initiated the Phase Ib DIVA trial, evaluating vididencel in combination with venetoclax and azacitidine (Ven+Aza) in newly diagnosed acute myeloid leukaemia (AML) patients with measurable residual disease (MRD) who are considered unfit for...

Mendus is drawing SEK16.5m under the second tranche of its SEK50m loan facility with Fenja Capital, taking total drawings to SEK46.5m, while the remaining SEK3.5m commitment will be cancelled. The parties have also agreed to extend the facility’s maturity...

Mendus’s Q226 results highlighted continued execution of its broadened vididencel strategy, with the first eight patients now enroled in the Phase Ib VITAL-CML study and an initial safety, tolerability and early molecular response readout expected in...